|
Nishida Y, Murase K, Isomoto H, et al. Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 2002;49: 678-82.
|
|
Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007;13: 918-32.
|
|
Márquez L, Pérez-Nievas BG, Gárate I, et al. Anti-inflammatory effects of Mangifera indica L. extract in a model of colitis. World J Gastroenterol 2010; 16: 4922-31.
|
|
Zhao P, Dong L, Luo JY, et al. Establishment of dextran sulfate sodium-induced ulcerative colitis model in rats. J Fourth Mil Med Univ 2005;26:1738-40.
|
|
Wallon C, Persborn M, J?nsson M, et al. Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology 2011; 140: 1597-607.
|
|
Hodges K, Kennedy L, Meng F, et al. Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. Transl Gastrointest Cancer 2012; 1: 138-50.
|
|
Wierzbicki M, Brzezińska-B?aszczyk E. The role of mast cells in the development of inflammatory bowel diseases. Postepy Hig Med Dosw (Online) 2008;62: 642-50.
|
|
Verma-Gandhu M, Verdu EF, Bercik P, et al. Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse. Gut 2007;56: 358-64.
|
|
Koon HW, Zhao D, Xu H, et al. Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. Am J Pathol 2008; 173: 400-10.
|
|
Liu L, Shang F, Morgan MJ, et al. Cyclooxygenase- dependent alterations in substance P-mediated contractility and tachykinin NK1 receptor expression in the colonic circular muscle of patients with slow transit constipation. J Pharmacol Exp Ther 2009; 329: 282-9.
|
|
Koon HW, Zhao D, Zhan Y, et al. Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J Immunol 2006;176:5050-9.
|
|
Tavano F, di Mola FF, Latiano A, et al. Neuroimmune in-teractions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on substance P serum levels. J Crohns Colitis 2012; 6: 563-70.
|
|
Watanabe T, Kubota Y, Muto T. Substance P containing nerve fibers in ulcerative colitis. Int J Colorectal Dis 1998; 13: 61-7.
|
|
Vento P, Kiviluoto T, Ker?nen U, et al. Quantitative comparison of growth-associated protein-43 and substance P in ulcerative colitis. J Histochem Cytochem 2001;49: 749-58.
|
|
ter Beek WP, Biemond I, Muller ES, et al. Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry. Neuropeptides 2007; 41: 301-6.
|
|
Koon HW, Shih D, Karagiannides I, et al. Substance P modulates colitis-associated fibrosis. Am J Pathol 2010; 177: 2300-9.
|
|
Rijnierse A, van Zijl KM, Koster AS, et al. Beneficial effect of tachykinin NK1 receptor antagonism in the development of hapten-induced colitis in mice. Eur J Pharmacol 2006; 548: 150-7.
|
|
Kulka M, Sheen CH, Tancowny BP, et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123: 398-410.
|
|
Lee CM, Kumar RK, Lubowski DZ, et al. Neuropeptides and nerve growth in inflammatory bowel diseases: a quantitative immunohistochemical study. Dig Dis Sci 2002; 47: 495-502.
|
|
Baticic L, Detel D, Kucic N, et al. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS- induced model of colitis in mice. J Cell Biochem 2011; 112: 3322-33.
|
|
Schepens MA, Vink C, Schonewille AJ, et al. Dietary heme adversely affects experimental colitis in rats, despite heat-shock protein induction. Nutrition 2011; 27: 590-7.
|